PATENT CLAIM ANALYSIS

Application Number: 15967607
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-08
Patent Classification: ["514", "254090"]

Abstract:
The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Claim (Index 17):
The method according to  claim 16 , wherein the pharmaceutically acceptable salt of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone is its monoethanesulfonate salt.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.67742
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12720663', '15590487', '15534527', '15561209', '14647939']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7438335331246068
- 35 USC 102 Novelty (BERT): 0.5243036061193975
- Combined Prediction Score: 0.7218805404240858
- Mean Citation Score: 242.814172
- Max Citation Score: 311.17834
- Similarity Product: 242.17203264017223

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test